Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate

Tvardi Therapeutics (NASDAQ: TVRD) reported a Q4 loss of $(0.78) per share, missing the analyst consensus estimate of $(0.68) by 15.38%. This represents an 84.21% increase in losses compared to $(4.94) per share from the same period last year.